Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tremelimumba

Bristol-Myers Squibb (BMS) building

BMS hails Opdivo and Yervoy combo in melanoma

New PD-1 therapy shines against the world’s first immunotherapy for skin cancer

- PMLiVE

MedImmune and Immunocore to join on melanoma trials

Will trial MEDI4736 in combination with tremelimumab

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

- PMLiVE

AZ’s Onglyza may increase mortality, says FDA

Kombiglyze also under scrutiny

- PMLiVE

PD-1 cancer market overrated, says new report

The immuno-oncology market for new oncology drugs may be worth half of current expectations

- PMLiVE

Merck’s Keytruda beats BMS’ Yervoy in melanoma face-off

Both firms competing for a leading share in the highly competitive skin cancer drug market

- PMLiVE

Keytruda is UK’s first early-access medicine

Merck’s melanoma therapy accepted under the UK’s EAMS

Bristol-Myers Squibb (BMS) building

Opdivo gains new US lung cancer licence

Adds to Bristol-Myers Squibb’s therapeutic vaccine’s melanoma indication

- PMLiVE

Roche’s Zelboraf combination to receive priority FDA review

US regulator to assess drug's use with cobimetinib for melanoma within six months

- PMLiVE

AZ loses Pulmicort Respules protection in US

Court also denied AZ’s request for a permanent injunction

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

- PMLiVE

Melanoma charity uses shock tactics in new awareness campaign

Mollie's Fund strives to educate sunbed users about the skin cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links